Journal name: World Journal of Pharmaceutical Research
Original article title: Pharmacological intervention at huntington's disease
The WJPR includes peer-reviewed publications such as scientific research papers, reports, review articles, company news, thesis reports and case studies in areas of Biology, Pharmaceutical industries and Chemical technology while incorporating ancient fields of knowledge such combining Ayurveda with scientific data.
This page presents a generated summary with additional references; See source (below) for actual content.
Subtitle: a review study
Original source:
This page is merely a summary which is automatically generated hence you should visit the source to read the original article which includes the author, publication date, notes and references.
Amulya Jindal, Ankit Lodhi, Deepak Tomar and Dhananjay Taumar
World Journal of Pharmaceutical Research:
(An ISO 9001:2015 Certified International Journal)
Full text available for: Pharmacological intervention at huntington's disease
Source type: An International Peer Reviewed Journal for Pharmaceutical and Medical and Scientific Research
Doi: 10.20959/wjpr20237-28080
Copyright (license): WJPR: All rights reserved
Summary of article contents:
Introduction
Huntington's disease (HGD) is a hereditary neurodegenerative disorder characterized by autosomal dominant inheritance, primarily affecting individuals of Eastern European descent. It manifests between the ages of 30 and 50 and leads to progressive motor, cognitive, and psychological decline due to the gradual degeneration of nerve cells in the brain. The disease is linked to a mutation in the Huntington gene, specifically a CAG trinucleotide repeat expansion on chromosome 4. Currently, there is no cure for HGD, but symptomatic treatment options are being explored, aiming to improve the quality of life for affected individuals.
Pharmacological Intervention for Chorea
Chorea, a hallmark symptom of HGD, presents as uncontrolled, dance-like movements and can severely impact daily functioning. The primary pharmacological intervention has included dopamine-depleting agents, most notably tetrabenazine (TBZ). TBZ has shown effectiveness in reducing chorea severity in several clinical trials, although potential side effects such as sedation, depression, and parkinsonism often limit its use. Other traditional antipsychotics, like haloperidol and fluphenazine, have also been utilized, but their efficacy varies, emphasizing the need for careful patient monitoring.
Treatment of Psychiatric Symptoms
Psychiatric symptoms in HGD, including depression, anxiety, and psychosis, contribute significantly to the patients' overall distress and can complicate treatment efforts. Various studies have reported outcomes with antidepressants like fluoxetine, though findings indicate limited efficacy in non-depressed patients. Antipsychotic medications, including risperidone and olanzapine, have been used to manage psychotic symptoms, with varying degrees of success. A multimodal approach to treatment is often necessary, combining pharmacological and behavioral strategies to address the comprehensive mental health needs of individuals with HGD.
The Search for Neuroprotective Treatments
In recent years, research has focused on potential neuroprotective therapies that target the underlying mechanisms of HGD. Innovations in biochemistry and genetics are paving the way for new treatments that could slow disease progression. Compounds like coenzyme Q10 and creatine have been explored for their neuroprotective properties, but the results have been mixed. Additionally, ongoing clinical trials aim to assess the viability of various glutamatergic inhibitors and other compounds that reduce neuronal apoptosis, showing promise for future treatment options.
Conclusion
The management of Huntington's disease remains complex, necessitating a comprehensive understanding of its genetic basis, symptomatology, and therapeutic approaches. While pharmacological interventions can alleviate some symptoms, no cures exist at this time. The pursuit of effective neuroprotective therapies is underway, fueled by advances in genetic research and clinical trials. Ongoing efforts to optimize symptomatic treatment and develop disease-modifying strategies offer hope for improving outcomes and enhancing the quality of life for those living with HGD.
FAQ section (important questions/answers):
What is Huntington's disease and how does it affect individuals?
Huntington's disease is a genetic neurological disorder causing progressive motor, cognitive, and behavioral symptoms. It leads to the degeneration of nerve cells in the brain, typically manifesting between ages 30 to 50.
How is Huntington's disease inherited and what causes it?
Huntington's disease is inherited in an autosomal dominant manner. It is caused by a mutation in the HTT gene on chromosome 4, characterized by repeated CAG sequences, leading to an abnormal protein.
What are the main symptoms associated with Huntington's disease?
Symptoms include uncontrollable jerking, writhing movements, cognitive decline, psychiatric disorders, and behavioral changes. Motor symptoms like rigidity and bradykinesia also occur, severely impacting quality of life.
Are there any effective treatments currently available for Huntington's disease?
Currently, there is no cure for Huntington's disease. Treatment mainly focuses on symptom management using medications such as tetrabenazine for chorea and antidepressants for behavioral symptoms.
What pharmacological interventions are used to manage chorea in Huntington's disease?
Pharmacological treatments for chorea include dopamine depleting agents like tetrabenazine, traditional neuroleptics, and some GABAergic drugs, aiming to reduce involuntary movements.
Is there ongoing research for new treatments or therapies for Huntington's disease?
Yes, research is ongoing to explore neuroprotective therapies, genetic studies, and drug trials focusing on symptom relief, disease modification, and potential cures.
Glossary definitions and references:
Scientific and Ayurvedic Glossary list for “Pharmacological intervention at huntingtonand#039;s disease”. This list explains important keywords that occur in this article and links it to the glossary for a better understanding of that concept in the context of Ayurveda and other topics.
1) Disease:
Diseases encompass various medical conditions, including Huntington's disease, that affect individuals' health and wellbeing. Understanding the broader context of diseases is essential for comprehensive healthcare strategies that address not only symptoms but also the psychological and social aspects of living with chronic illness.
2) Study (Studying):
The study refers specifically to the systematic review of existing research on pharmacological interventions for Huntington's disease conducted by the authors. This comprehensive analysis plays a crucial role in synthesizing credible evidence, guiding healthcare professionals in selecting appropriate treatments, and underpinning future research directions in HD therapeutics.
3) Drug:
Drugs denote the various pharmaceutical agents trialed or proposed for managing symptoms of Huntington's disease. Understanding the effects, mechanisms, and potential side effects of these drugs is crucial for developing effective therapeutic regimens, ultimately leading to improved patient care and outcomes in managing this challenging neurodegenerative condition.
4) Quality:
The quality refers to the standards and criteria used to evaluate research studies on Huntington's disease pharmacological interventions. High-quality studies are essential to ensure that findings are valid, reliable, and can be applied to clinical practice, ultimately benefiting patient care and treatment efficacy.
5) Depression:
Depression is a common psychiatric symptom experienced by patients with Huntington's disease. It's critical to evaluate and address depression as it significantly impacts quality of life and overall functioning. Understanding the relationship between HD and depression informs treatment strategies, highlighting the need for holistic care that includes mental health support.
6) Pharmacological:
Pharmacological pertains to the use of medications to treat Huntington's disease, focusing on symptom management rather than curing the underlying condition. This involves understanding how drugs interact with the nervous system. Effective pharmacological strategies are central to enhancing the quality of life for individuals with HD through symptom relief.
7) Medicine:
The medicine refers to pharmacological treatments specifically designated for managing the symptoms of Huntington's disease. These targeted treatments aim to alleviate various aspects of the condition's effects, emphasizing the importance of ongoing research and development within this therapeutic area.
8) Anxiety:
Anxiety is a prevalent symptom observed in individuals with Huntington's disease, impacting their emotional wellbeing and quality of life. Addressing anxiety through appropriate therapeutic interventions is essential, as it can complicate disease management. Understanding its prevalence within the context of HD is crucial for holistic patient care.
9) Table:
Table refers to the structured presentation of data summarizing studies and findings related to Huntington's disease treatment. Tables facilitate easy comparison and analysis of results, showcasing the efficacy and safety of various pharmacological interventions in a clear, concise format that enhances understanding for healthcare professionals.
10) Psychosis:
Psychosis refers to the disconnection from reality experienced by some patients with Huntington's disease, manifesting as hallucinations or delusions. Understanding this symptom is crucial for tailoring treatment plans, as effective management of psychosis can significantly improve patient quality of life and overall mental health outcomes.
11) Life:
Life refers to the quality of life experienced by individuals with Huntington's disease, which is often severely affected due to progressive motor, cognitive, and psychiatric symptoms. Interventions aimed at improving symptoms through pharmacological approaches are essential for enhancing the overall livelihood and well-being of patients.
12) Obsession:
Obsession refers to recurring, intrusive thoughts or behaviors that can occur in patients with Huntington's disease. Understanding and addressing obsessive symptoms is important to improve mental health and quality of life. Treatment strategies often involve pharmacological interventions aimed at reducing these debilitating experiences.
13) Puri:
Puri may refer to studies or individuals involved in Huntington's disease research. In this context, Puri's work or findings could contribute to the evidence base regarding pharmacological interventions, furthering understanding of effective treatments for managing symptoms or the disease's progression.
14) Hand:
Hand may refer to activities of daily living affected by Huntington's disease, such as writing, dressing, or other fine motor functions. Understanding the impact of HD on hand function is critical for developing adaptive strategies and therapies to maintain independence and quality of life in patients.
15) Cancer:
Cancer, while not directly linked to Huntington's disease, may arise as a concern in the context of genetic predispositions. Understanding the overall health of patients with HD, including potential cancer risks, is essential for holistic treatment planning and monitoring, ensuring comprehensive patient care.
16) Pur:
Poor denotes a state of diminished quality, often related to the ineffective management of symptoms in Huntington's disease. Poor outcomes in treatment could relate to inadequate therapeutic response, highlighting the need for ongoing research and development of more effective pharmacological therapies to enhance patient care.
17) Relative:
Relative refers to family connections, particularly in the context of Huntington's disease genetics. The hereditary nature of HD necessitates understanding the risks faced by relatives. Genetic counseling and education for relatives are integral parts of managing familial health related to this progressive condition.
18) Account:
Accounts refer to detailed narratives or reports of symptoms and treatment experiences from individuals with Huntington's disease. These accounts provide valuable insights into the lived experiences of patients, informing healthcare practices and guiding research towards addressing real-world challenges faced by affected individuals.
19) Reason:
Reason refers to the underlying causes or justifications for studying Huntington's disease and its treatments. Understanding the reasons behind ongoing research and clinical trials is crucial for advancing knowledge and developing more effective therapies that can positively impact patient quality of life.
20) India:
India may refer to the geographical context of the study or research initiatives related to Huntington's disease conducted within this nation. Local studies can provide valuable insights into the prevalence, genetic factors, and treatment responses specific to populations within India, enhancing overall healthcare strategies.
21) Death:
Death signifies the ultimate consequence of advanced Huntington's disease, emphasizing the condition's progressive and debilitating nature. Understanding mortality related to HD is crucial for developing care strategies aimed at prolonging life and enhancing the quality of care during the progression of the disease.
22) Mud:
Mood relates to the emotional states experienced by individuals with Huntington's disease, including fluctuations that can affect behavior and quality of life. Targeting mood disturbances through appropriate treatments is essential for holistic management of Huntington's disease, necessitating attention in clinical care.
23) Performance:
Performances relate to the functional and cognitive outcomes measured in clinical trials for Huntington's disease treatments. Evaluating performances is crucial for assessing the impact of pharmacological interventions on daily living skills, which in turn affects patient quality of life and independence.
24) Mutation:
Mutation pertains to the genetic changes associated with Huntington's disease, specifically in the HTT gene. Understanding the nuances of genetic mutations is vital for diagnosis, treatment considerations, and exploring potential therapeutic avenues aimed at targeting the underlying genetic cause of the disease.
25) Language:
Language plays a role in study dissemination, communication of findings, and patient education. Clarity of language in discussing Huntington's disease and treatment options is essential for ensuring that both healthcare providers and patients understand the complexities and implications surrounding this condition.
26) Delusion (Deluded):
Delusions refer to firmly held false beliefs, often one of the psychiatric manifestations in Huntington's disease. Understanding how delusions present in patients is necessary for tailoring treatment plans aimed at addressing these symptoms, ultimately improving their quality of life and mental health.
27) Epilepsy:
Epilepsy may occur as a comorbidity in patients with Huntington's disease, complicating the clinical picture. Understanding the interplay between HD and seizures informs treatment strategies and necessitates a multidisciplinary approach for comprehensive patient care that addresses all neurological domains involved.
28) Company:
Company may refer to the organizations or entities involved in conducting research or developing therapies for Huntington's disease. Collaboration between companies can enhance resource allocation and foster innovative treatment solutions aimed at managing this complex neurodegenerative condition.
29) Family:
Family is significant in the context of Huntington's disease due to its hereditary nature. Familial support is crucial for patients navigating the challenges of HD. Education and genetic counseling for families help in understanding risks and managing the disease's impact on relatives.
30) Vega:
Vega might refer to specific studies or individuals contributing to Huntington's disease research. The contributions of researchers like Vega can greatly enhance the understanding of effective treatments and help bridge gaps in current scientific and medical discourse surrounding HD management.
31) Sign:
Sign refers to indicators or symptoms associated with Huntington's disease. Recognizing signs is critical for early diagnosis and intervention, influencing treatment efficacy and exploring new therapeutic pathways to address both the physical and psychological burden of the disease.
32) Pharmacotherapy:
Pharmacotherapy refers to the treatment of Huntington's disease primarily through medication. Understanding how different pharmacological agents affect symptoms enables healthcare providers to devise effective treatment plans tailored to individual patient needs, ultimately improving quality of life and disease management.
33) Trustworthiness:
Trustworthiness pertains to the reliability of research findings in Huntington's disease treatment studies. Establishing trust in study results is essential for clinical application, impacting treatment decisions made by healthcare providers and the overall perception of drug efficacy and safety by patients.
34) Reliability:
Reliability indicates the consistency and dependability of results obtained from studies on Huntington's disease treatments. Reliable findings are pivotal for clinical decision-making, influencing which therapies are adopted in practice and how effectively they are integrated into patient care.
35) Swallowing:
Swallowing difficulties often manifest in Huntington's disease, impacting nutrition and overall health. Understanding the challenges associated with swallowing is essential for developing supportive interventions and care strategies that ensure adequate nutrition and quality of life for affected individuals.
36) Irritation:
Irritation refers to heightened emotional states that may occur in Huntington's disease patients. Managing irritation is important for improving interpersonal relationships and overall emotional wellbeing, highlighting the need for pharmacological and psychosocial interventions tailored to help patients cope effectively.
37) Drowsiness:
Drowsiness is a common side effect associated with several medications used to treat symptoms of Huntington's disease. Monitoring drowsiness in patients is important to ensure safety and optimal functioning while addressing the symptoms effectively, balancing treatment efficacy with quality of life considerations.
38) Science (Scientific):
Science is the systematic pursuit of knowledge that informs the understanding and treatment of Huntington's disease. Scientific research is fundamental in developing effective therapies and improving patient care, underscoring the importance of evidence-based practices in neurodegenerative disease management.
39) Knowledge:
Knowledge encompasses the information and understanding gained through research on Huntington's disease. It forms the basis for clinical practice and therapeutic advancements, facilitating informed decision-making for healthcare providers and enhancing education about the condition for patients and their families.
40) Education:
Education plays a crucial role in raising awareness about Huntington's disease, its genetic implications, symptoms, and treatment options. Ensuring that patients, relatives, and healthcare providers have adequate knowledge fosters better management, support, and advocacy for affected individuals in their care journeys.
41) Toxicity:
Toxicity refers to the harmful effects that certain substances, including medications, can have on patients. Understanding toxicity is vital in developing safe pharmacological treatments for Huntington's disease, ensuring that the benefits outweigh any adverse effects associated with the drugs used for symptom management.
42) Dressing:
Dressing refers to the activities of daily living that can be significantly affected by Huntington's disease. Addressing dressing difficulties is crucial for maintaining patients' independence and dignity, emphasizing the need for occupational therapy and supportive care strategies to assist in daily activities.
43) Nausea:
Nausea may occur as a side effect of medications used to treat Huntington's disease or as a symptom of the disease itself. Understanding how nausea affects patients is essential for developing comprehensive treatment strategies that enhance quality of life while addressing medication tolerability.
44) Nature:
Nature refers to the inherent characteristics and genetic factors associated with Huntington's disease. Understanding the nature of the disease is crucial for diagnosing and developing targeted therapies. It also informs research into the molecular mechanisms underpinning disease progression and potential intervention points.
45) Summer:
Summer may refer to the time frame in clinical studies or to seasonal considerations in evaluating Huntington's disease treatments. Understanding timing and context in research can influence outcomes and assessments of treatment efficacy, necessitating a comprehensive view of various factors affecting clinical trials.
46) Animal:
Animal studies often serve as a model for understanding Huntington's disease mechanisms and testing potential therapies before moving to human trials. These studies are crucial for elucidating biological processes, drug efficacy, and safety profiles that guide subsequent clinical research in humans.
47) Farmer:
Farmer may refer to specific studies or contributions made by individuals with that surname, enhancing the understanding of Huntington's disease. Contributions from researchers like Farmer are integral to the body of knowledge surrounding HD, guiding future research and treatment development.
48) Thomas:
Thomas may denote a researcher or a study related to Huntington's disease, representing a part of the broader academic effort to understand and treat this condition. Contributions from researchers named Thomas can provide essential insights into the complexities of HD management.
49) Kalka:
Kalka refers to an institution or individual involved in Huntington's disease research or treatment. Understanding the contributions or findings from Kalka is important, as they can lead to better therapeutic strategies and enhanced understanding of this neurodegenerative condition.
50) Dance:
Dance may symbolize the involuntary movements characteristic of Huntington's disease, often described as dance-like chorea. Recognizing the nature of these movements is crucial for developing effective treatments aimed at reducing motor symptoms and improving patient quality of life.
51) Field:
Field refers to the area of study or research concerning Huntington's disease and related therapies. Within this field, collaborations, advancements, and discoveries contribute to enhancing understanding and treatment options for patients suffering from this complex neurodegenerative disorder.
52) Blood:
Blood may refer to the role of genetic testing and biomarkers in identifying Huntington's disease. Understanding blood markers assists in confirming diagnoses and can play a pivotal role in tracking disease progression and responses to various pharmacological treatments.
53) Bird:
Bird may refer to individuals, studies, or concepts related to Huntington's disease research. The contributions associated with the term can enhance the literature surrounding HD, providing valuable insights for future studies and therapeutic approaches aimed at improving patient outcomes.
54) Male:
Male may denote the gender-specific implications of Huntington's disease, particularly in relation to genetic transmission and symptom expression. Understanding how HD affects males can inform targeted research and treatment strategies, considering gender differences in disease manifestation and prognosis.
Other Science Concepts:
Discover the significance of concepts within the article: ‘Pharmacological intervention at huntingtonand#039;s disease’. Further sources in the context of Science might help you critically compare this page with similair documents:
Case studies, Randomized controlled trial, Clinical trial, Clinical studies, Clinical evaluation, Huntington's disease, Motor symptoms, Cognitive decline, Cognitive symptoms, Pharmacological intervention, Symptomatic Therapy, Genetic abnormalities, Neuroleptics, Prevalence studies, Antidepressant, Randomised controlled trial, Patient quality of life, Neuroleptic drug, Systematic literature review, Neurotransmitter balance.